


| | | |
|---|------------------------------------|--|
|  | SCHEDA TECNICA PRODOTTO | MOD C16-MY TULLE Rev. 2 Pag. 1 /7 |
|---|------------------------------------|--|

Ditta: Derma Sciences
Nome commerciale: Medihoney®
Codice Prodotto: vedi sotto

| | |
|---|--|
| Prodotto da | Derma Sciences Inc. 104 Shorting Road Toronto, Ontario M1S 3S4 Canada |
| Distribuito da | Integra LifeSciences Italy S.r.l. Strada 6, Palazzo N3 – Milanofiori 20089 ROZZANO - MI |
| Certificazione C.E. | CE0120 |
| Classe di rischio (93/42/EEC) | IIb |
| Codice CND | M040499 |
| REPERTORIO DM | <u>Vedi sotto:</u> art. 796 1383278 art. 797 1385627 |
| Descrizione completa:  | <p>MEDIHONEY® Tulle 3-Ply (3 pieghe alias 3 misure) è una medicazione in garza composta da un bendaggio in tulle resistente, impregnato di MEDIHONEY MEDICAL HONEY ANTIBATTERICO (20 gr minimo)</p> <p>Non è aderente. Non è assorbente.</p> <p>La sua azione permette di:</p> <ul style="list-style-type: none"> • fornire un ambiente umido ottimale per la guarigione della ferita; • proteggere la lesione creando una barriera antibatterica anche contro ceppi di batteri resistenti agli antibiotici; • rimuovere il cattivo odore; • ridurre il rischio di infezioni batteriche; • attivare un rapido ed efficace sbrigliamento autolitico di slough, tessuto necrotico e fibrina |
| Destinazione d'uso | <ul style="list-style-type: none"> • Ulcere agli arti inferiori; • Ulcere diabetiche • Lesioni da pressione • Ferite infette • Ferite irregolari • Ferite maleodoranti • Siti di impianto di cute (donatore e ricevente) • Ustioni (I° e II° grado) • Lesioni superficiali, come tagli, graffi, abrasioni • Ferite chirurgiche • Ferite necrotiche |

La medicazione Tulle Medihoney® è disponibile nelle seguenti misure:

| Codice | Descrizione | Q.tà per confezione |
|---------------|---|----------------------------|
| 796 | Medicazione Tulle 3-Ply Medihoney® chiuso 10 cm x 10 cm – semiaperto 10 cm x 20 cm – aperto 10 cm x 30 cm | 5 pz. |
| 797 | Medicazione Tulle 3-Ply Medihoney® chiuso 5 cm x 5 cm – semiaperto 5 cm x 10 cm – aperto 5 cm x 15 cm | 5 pz. |

| | |
|--|--|
| Condizioni di mantenimento/trasporto: | <ul style="list-style-type: none"> • Conservare a una temperatura massima di 25°C • Tenere al riparo da fonti di calore. • Tenere al riparo dai raggi diretti del sole. |
| Sterilizzazione: | |
| Prodotto Fornito Sterile | SI' |
| Metodo di sterilizzazione | Raggi gamma |
| Prodotto Sterilizzabile | NO |
| Shelf-life (durata della sterilità del prodotto) | 3 anni |
| Monouso: | SI' |
| Materiali costituenti il DM: | La medicazione Tulle Medihoney® è in leptospermum antibatterico (Manuka) e miele (minimo 20 g). |
| Confezionamento: | Vedi foglietto informativo |
| Prodotto Latex Free | SI' |
| Modalità di impiego e avvertenze: | Fare riferimento al foglietto illustrativo interno contenuto nella confezione del prodotto. |

Reference List

1. Acton C, Dunwoody G. The use of medical grade honey in clinical practice. *Brit J Nurs* 2008; 17(20): S38-S44. (**)
2. Acton C. Medihoney™: a complete wound bed preparation product. *Brit J Nurs* 2008; 17(11): S44-S48. (**)
3. Acton C. Treatment of a venous leg ulcer found in an intravenous drug user. *Wound Essentials* 2008; 3:69-71. (**)
4. Albietz JM, Lenton LM. Effect of antibacterial honey on the ocular flora in tear deficiency and meibomian gland disease. *Cornea* 2006; 25(9):1012-1019. (*)
5. Alcaraz A, Kelly J. Treatment of an infected venous leg ulcer with honey dressings. *British J Nursing* 2002; 11(13):859-866. (*)
6. Amaya R. Safety and efficacy of active *Leptospermum* honey in neonatal and paediatric wound debridement. *J Wound Care* 2015; 24(3): 97-103. (*)
7. Amaya R. Little patients, big outcomes: the role of MEDIHONEY® in pediatric wound care. *Ostomy Wound Manage* 2014;60(8):8.
8. Bardy J, Molassiotis A, Ryder WD, et al. A double-blind, placebo-controlled, randomized trial of active manuka honey and standard oral care for radiation induced oral mucositis. *Br J Oral Maxillofac Surg*. 2012 Apr; 50(3): 221-6. (Λ)
9. Bateman S, Graham T. The use of Medihoney™ Antibacterial wound gel on surgical wounds post coronary artery bypass grafts (CABG). *Wounds UK* 2007; 3(3):76-83. (**)
10. Biglari B, vd Linden PH, Simon A, Aytac S, Gerner HJ, Moghaddam A. Use of Medihoney as a non-surgical therapy for chronic pressure ulcers in patients with spinal cord injury. *Spinal Cord* 2012; 50(2):165-169. (*)
11. Biglari B, Moghaddam A, Santos K, et. al. Multicentre prospective observational study on professional wound care using honey (Medihoney). *Int Wound Journal*. 2012;10(3):252-259. (*,**)
12. Bittmann S, Luchter E, Thiel M, et al. Does honey have a role in paediatric wound management? *Br J Nurs* 2011; 19(15):S19-24. (review)
13. Blaser G, Santos K, Bode U, Vetter H, Simon A. Effect of medical honey on wounds colonized or infected with MRSA. *J Wound Care* 2007; 16(8):325-328. (*)
14. Cadogen J. The use of honey to treat an ulcer on the heel of a person with diabetes. *The Diabetic Foot Journal* 2008; 11(1):43-45. (*, **)
15. Chaiken N. Pressure ulceration and the use of active *leptospermum* honey for debridement and healing. *Ostomy Wound Manage* 2010; 56(5):
16. Chapman L. Use of honey on a neuropathic ulcer. *Journal of Community Nursing* 2009; 23(2):10-14. (**)
17. Chernev I, Liguori P, Senno S, et al. Combined noncontact, low-frequency ultrasound and medical honey for the treatment of chronic wounds: a case series. *J Wound Ostomy Continence Nurs* July 2010; 37(4):421-425. (***)
18. Cooper J. Wound management following orbital exenteration surgery. *Brit J Nurs* 2009; 18(6):S4-S14. (**)
19. Cooper R, Gray D. Is manuka honey a credible alternative to silver in wound care? *Wound UK* 2012; 8(4):54-64. (*)
20. Cutting K. Honey and contemporary wound care: an overview. *Ostomy Wound Manage* 2007; 53(11):49-54. (*)
21. Drain J, Fleming M. Palliative management of malodorous squamous cell carcinoma of the oral cavity with manuka honey. *J Wound Ostomy Continence Nurs* 2015, 42(2):190-192. (*, ***)
22. Dunford C, Hanano R. Acceptability to patients of a honey dressing for non-healing venous leg ulcers. *J Wound Care* 2004; 13(5):193-197. (*)
23. Dunford C. Treatment of a wound infection in a patient with mantle cell lymphoma. *Brit J Nurs* 2001; 10(16): 1058-1065. (*)
24. Dunford C. The use of honey-derived dressings to promote effective wound management. *Professional Nurse* 2005; 20(8):35-38. (*)

25. Fitzmaurice SD, Sivamani RK, Isseroff RR. Antioxidant therapies for wound healing: a clinical guide to currently commercially available products. *Skin Pharmacol Physiol* 2011; 24(3):113-26. (*)
26. Forbes TA, Shaw L, Quinlan C. Topical honey in the management of pediatric peritoneal dialysis exit sites. *Perit Dial Int* 2016; 36(6):684-7**
27. Gethin G, Cowman S. Bacteriological changes in sloughy venous leg ulcers treated with manuka honey or hydrogel: an RCT. *J Wound Care* 2008; 17(6):241-247. (*)
28. Gethin G, Cowman S. Manuka honey vs hydrogel – a prospective, open label, multicentre, randomized controlled trial to compare desloughing efficacy and healing outcomes in venous ulcers. *J Clin Nurs* 2009; 18(3):466-74.
29. Gethin G, Cowman S. Case series of use of Manuka honey in leg ulceration. *Int Wound J* 2005; 2(1):10-15. (*)
30. Grant T. Treating pilonidal sinus wounds with an antibacterial wound gel after incision and drainage. *Wounds UK* 2009; 5(1):78-80. (**)
31. Gray C., Ishii F. Using active *Leptospermum* honey in the debridement process: 6 challenging cases from the inner city. *Ostomy Wound Manage* 2015; 61 (4) 63-66. (*)
32. Greenwood M, Handsaker J. Honey and Medihoney® Barrier Cream: their role in protecting and repairing skin. *Br J Community Nurs* 2012; 17(12); S32-S37. (^^)
33. Johnson C, Katzman M. Managing skin tears with Medihoney®. *Ostomy Wound Manage* 2015; 61(6):8-.
34. Johnson D, Badre S, Pascoe E, et al. Antibacterial honey for the prevention of peritoneal-dialysis-related infections (Honey Pot): A randomized trial. *Lancet Inf Dis* 2014; 14(1):23-30. (**)
35. Johnson D, van Eps C, Mudge W, et al. Randomized, controlled trial of topical exit-site application of honey (Medihoney™) versus Mupirocin for the prevention of catheter-associated infections in hemodialysis patients. *J Am Soc Nephrol* 2005; 16(5):1456-62. (*)
36. Johnson D, Clark C, Isbel N, et al. The HoneyPot Study Protocol: A randomized controlled trial of exit-site application of Medihoney Antibacterial Wound Gel for the prevention of catheter-associated infections in peritoneal dialysis patients. *Peritoneal Dialysis International* 2009; 29(3):303-309. (**)
37. Jull A, Walker N, Parag V, et al. Randomized clinical trial of honey-impregnated dressings for venous leg ulcers. *Br J Surg* 2008; 95(2):175-182. (***)
38. Kallen A, Arduino M, Patel P. Preventing infections in patients undergoing hemodialysis. *Expert Rev Anti Infect Ther* 2010; 8(6):643-655. (**)
39. Kamaratos AV, Tzirogiannis KN, Iraklianos SA, et al. Manuka Honey-impregnated dressings in the treatment of neuropathic diabetic foot ulcers. *Int Wound J* 2014; 11(3):259-63 (^^^)
40. Kroeger K. [Honig und Wundheilung: The use of medical honey in wound healing.] *Wound Management* 2008; 3:64-70. (German). (****)
41. Langemo D, Hanson D, Anderson J, et al. Use of honey for wound healing. *Adv Skin Wound Care* 2009; 22(3):113-118. (****)
42. Lee VS, Humphreys IM, Purcell PL, Davis GE. Manuka honey sinus irrigation for the treatment of chronic rhinosinusitis: a randomized controlled trial *Int Forum Allergy Rhinol* 2016; doi 10.1002/alr.21898 [epub ahead of print]*
43. Mohr LD, Reyna R, Amaya R. Neonatal case series using active *Leptospermum* honey. *J Wound Ostomy Continence Nurs* 2014; 41(3):213-8 (**, ***, ****)
44. Nijhuis WA, Houwing RH, Van der Zwet WC, Jansman FG. A randomised trial of honey barrier cream versus zinc oxide ointment. *Brit J Nurs* 2012;21(20, Supp):S10-3 (^^)
45. Old N. The Medicine of the Manuka: an investigation of the usages and methods for utilization of honey derived from the pollen of *Leptospermum scoparium* in holistic nursing practice. *J Holistic Nurs*: 2013 Sep; 31(3): 200-3. (*, ***, ****)
46. Pieper B. Honey-based dressings and wound care: An option for care in the United States. *J Wound, Ostomy and Continence Nurs* 2009; 36(1):60-6. (
47. Rabindranath K, Bansal T, Adams J. Systematic review of antimicrobials for the prevention of haemodialysis catheter-related infections. *Nephrology Dialysis Transplantation Nephrol Dial Transplant*. 2009; 24(12):3763-74. (**)

REFERENCED PRODUCTS: *MEDIHONEY® Paste/Medical Honey, **MEDIHONEY® Gel, ***MEDIHONEY® Calcium Alginate/Apinate, ****MEDIHONEY® Honeycolloid™/Gel Sheet, ^Comvita Wound Care 18+, ^^MEDIHONEY® Barrier Cream, ^^MEDIHONEY® TULLE Dressing

48. Regulski M. A novel wound care dressing for chronic venous leg ulcerations. *Podiatry Management* Nov/Dec 2008; pgs 235-46.
49. Robson V. *Leptospermum* honey used as a debriding agent. *Nurse 2 Nurse* 2002; 2(11):66-8.
50. Robson V, Martin L, Cooper R. The use of *Leptospermum* honey on chronic wounds in breast care. IN: White R, Cooper R, Molan P (eds.) *HONEY: a modern wound management product*. Aberdeen: Wounds UK Publishing 2005:103-11 (*)
51. Robson V. The use of *Leptospermum* honey in chronic wound management. IN: White R, Cooper R, Molan P (eds.) *HONEY: a modern wound management product*. Aberdeen: Wounds UK Publishing 2005:79-88. (*)
52. Robson V, Ehsan M. The use of honey in wound management following ENT surgery. *Primary Intention Journal* 2007; 15(4):176-180. (*)
53. Robson V, Cooper R. Using *Leptospermum* honey to manage wounds impaired by radiotherapy: A case series. *Ostomy Wound Manage* 2009; 55(1), 38-47. (*)
54. Robson V, R. Cooper. The use of *Leptospermum* honey in chronic wound management impaired by radiotherapy: a case series. *Ostomy Wound Manage* 2009; 55(1):38-47. (*)
55. Robson V, Dodd S, Thomas S. Standardized antibacterial honey (Medihoney™) with standard therapy in wound care: randomized clinical trial. *Journal of Advanced Nursing* 2009; 65(3):565-75. (*)
56. Robson V, Yorke J, Sen R, et al. Randomised controlled feasibility trial on the use of medical grade honey following microvascular free tissue transfer to reduce the incidence of wound infection. *Br J Oral Maxillofac Surg* 2012; 50(4):321-7.
57. Rothmeier N, Abu-Jawad J, Arnolds D, et al. [Die Behandlung chronischer Wunden im Kopf-Hals-Bereich nach Radiatio mit medizinischem Honig: The treatment of chronic wounds in the head and neck area after radiotherapy with medical honey.] (German) *Laryngorhinootologie* 2014; 93(9): 612-18.
58. Sampiero-de-Luis JM, Lopez-Cabrera P, Bernal-Martinez A, et al. Experiencia con Nexobrid para el desbridamiento enzimático de quemaduras faciales seguido de tratamiento conservador con Medihoney® [Experience with NexoBrid in enzymatic debridement of facial burns followed by conservative treatment with Medihoney®]. *Cir Plast Iberolatinoam* 2016; <http://dx.doi.org/10.4321/S0376-78922016000200007>
59. Sare J. Leg ulcer management with topical medical honey. *Br J Community Nurs* 2008; 13(9):S22-31. (**)
60. Schumacher H. Use of medical honey in patients with chronic venous leg ulcers after split-skin grafting. *J Wound Care* 2004; 13(10):451-452. (*)
61. Simon A, Sofka K, Wiszniewsky G, et al. Wound care with antibacterial honey (Medihoney™) in pediatric hematologic-oncology. *Support Care Cancer* 2006; 14(1):91-7. (*)
62. Simon A, Blaser G, Santos K. Honey in pediatric care and oncology. IN Cooper R, Molan P, White R (eds.) *HONEY: a modern wound management product*. Aberdeen: Wounds UK Publishing 2008:153-167. (*)
63. Simon A, Traynor K, Santos K, et al. Medical honey for wound care – still the 'latest resort'? *Evid Based Complement Alternat Med* 2008; 6(2):165-173. (*)
64. Smith T, Legel K, Hanft J. Topical *Leptospermum* honey (Medihoney) in recalcitrant venous leg wounds: A preliminary case series. *Adv Skin Wound Care* 2009; 22(2):68-71. (***)
65. Sofka K, Wiszniewsky SG, Blaser G, et al. Antibakterielle Honig (Medihoney™) zur Wundpflege - Wundantiseptis bei pädiatrischen Patienten in der Hämatologie-Onkologie? [Antibacterial Honey (Medihoney™) for Wound care - an antiseptic option for wound care in pediatric oncology?]. *Krankenhaus-Hygiene und Infektionsverhütung* 2004; 26(5):183-7. (*)
66. Stephen-Haynes J. Achieving clinical outcomes: The use of honey. *Wound Essentials* 2011; 6:14-19.
67. Thamboo A, Thamboo A, Philpott C, Javer A. Single-blind study of manuka honey in allergic fungal rhino sinusitis. *J Otolaryngol Head Neck Surg.* 2011; 40(3):238-243. (*)
68. White R, Acton C. Honey in modern wound management. *MIMS Dermatology* 2006; 2(1):40-42. (**)
69. Alnaimat S, Wainwright M, Al'Abiri K. Antibacterial potential of honey from different origins: A comparison with manuka honey. *J Microbiol Biotech Food Sci.* 2012; 1(5) 1328-38. (*)
70. Blair S, Cokcetin N, Carter D. The unusual antibacterial activity of medical-grade *Leptospermum* honey: antibacterial spectrum, resistance and transcriptome analysis. *Eur J Clin Microbiol Infect Dis* 2009; 8(10):1199-1208. (*)
71. Camplin A, Maddocks S. Manuka honey treatment of biofilms of *Pseudomonas aeruginosa* results in the emergence of isolates with increased honey resistance. *Ann Clin Microbiol Antimicrob* 2014, 13:19.
72. Cooper R. Inhibition of biofilms with honey. PERSE Biofilm Study Day, 11 May 2017, Paris France.
73. Cooper R. Honey for wound care in the 21st century. *J Wound Care* 2016; 25(9):544-52.

74. Cooper R, Jenkins L, Henriques A, et al. Absence of bacterial resistance to medical-grade manuka honey. *Eur J Clin Microbiol Infect Dis* 2010; 29(10):1237-41. (*)
75. Cooper R, Jenkins L, Hooper S. Inhibition of biofilms of *Pseudomonas aeruginosa* by Medihoney in vitro. *J Wound Care* 2014; 23(3):93-104.
76. Cooper R, Jenkins L. A comparison between medical grade honey and table honeys in relation to antimicrobial efficacy. *Wounds* 2009; 21(2):29-36. (*)
77. Cooper RA, Halas E, Molan PC. The efficacy of honey in inhibiting strains of *Pseudomonas aeruginosa* from infected burns. *J Burn Care Rehabil* 2002; 23:366-70.
78. George N, Cutting K. Antibacterial honey (Medihoney™): *in-vitro* activity against clinical isolates of MRSA, VRE, and other multi-resistant gram-negative organisms including *Pseudomonas aeruginosa*. *Wounds* 2007; 19(9):231-236. (*)
79. Halstead FD, Webber MA, Rauf M, et al. In vitro activity of an engineered honey, medical grade honeys, and antimicrobial wound dressings against biofilm producing clinical bacterial isolates. *J Wound Care* 2016, 25(2):93-4. (*)
80. Hammond EN, Donkor ES. Antibacterial effect of Manuka honey on *Clostridium difficile*. *BMC Res Notes* 2013 May 7; 6(1): 188. (^)
81. Igelbrink D, Koburger T, Simon A, Kramer A. Mikrobiozide Wirksamkeit von Medihoney™ [Microbiocidal efficacy of Medihoney™]. *GMS Krankenhaushygiene Interdisziplinär* 2007; 2(2):Doc50. (*)
82. Irish J, Carter DA, Shokohi T, Blair S. Honey has an antifungal effect against *Candida* species. *Medical Mycology* 2006; 44:289-91. (*)
83. Jenkins RE, Cooper RA, Burton NF. A laboratory survey of the antimicrobial properties of honey-containing dressings. *EWMA Journal* 2008; 8(3):11-15. (***)
84. Jenkins R, Burton N, Cooper R. Effect of manuka honey on the expression of universal stress protein A in methicillin-resistant *Staphylococcus aureus*. *Int J Antimicrob Agents* 2011; 37:373-6.
85. Jenkins R, Cooper R. Synergy between oxacillin and manuka honey sensitizes methicillin-resistant *Staphylococcus aureus* to oxacillin. *J Antimicrob Chemother* 2012; 67(6):1405-7. (*)
86. Jenkins R, Cooper R. Improving antibiotic activity against wound pathogens with manuka honey in vitro. *PLoS ONE* 2012; 7(9):e45600. (*)
87. Jenkins R, Burton N, Cooper R. Proteomic and genomic analysis of methicillin-resistant *Staphylococcus aureus* (MRSA) exposed to manuka honey in vitro demonstrated down-regulation of virulence markers. *J Antimicrob Chemother* 2013; 69(3):603-15. (*)
88. Jenkins R, Wootton M, Howe R, Cooper R. A demonstration of the susceptibility of clinical isolates obtained from cystic fibrosis patients to manuka honey. *Arch Microbiol.* 2015; 197(4):597-601. (*)
89. Henriques AF, Jenkins RE, Burton NF, Cooper RA. The intracellular effects of manuka honey on *Staphylococcus aureus*. *Eur J Clin Microbiol Inf Dis* 2010; 29:45-50. (*)
90. Kronda JM, Cooper RA, Maddocks SE. Manuka honey inhibits siderophore production in *Pseudomonas aeruginosa*. *J Appl Microbiol* 2013; 115(1): 86-90. (*)
91. Lu J, Carter DA, Turnbull L, et al. The effect of New Zealand kanuka, manuka and clover Honeys on bacterial growth dynamics and cellular morphology varies according to the species. *PLoS ONE* 2013; 8(2):e55898. doi:10.1371/journal.pone.0055898.*
92. Lu et al. Manuka-type honeys can eradicate biofilms produced by *Staphylococcus aureus* strains with different biofilm-forming abilities. *Peer J.* 2014; 2:e326. doi: 10.7717/peerj.326. eCollection 2014.
93. Lusby PE, Coombes AL, Wilkinson JM. Bactericidal activity of different honeys against pathogenic bacteria. *Arch Med Res* 2005; 36:454-467. (*)
94. Maddocks SE, Jenkins RE, Rowlands RS, et al. Manuka honey inhibits adhesion and invasion of medically important bacteria (in vitro). *Future Microbiol.* 2013 Dec; 8: 1523-36. Doi: 10.2217/fmb.13.126 (*)
95. Maddocks S, Lopez M, Rowlands R, Cooper R. Manuka honey inhibits the development of *Streptococcus pyogenes* biofilms and causes reduced expression of two fibronectin binding proteins. *Microbiology (Reading, England)* 2012; 158(Pt. 3):781-790. (*)
95. Maddocks S, Lopez M, Rowlands R, Cooper R. Manuka honey inhibits the development of *Streptococcus pyogenes* biofilms and causes reduced expression of two fibronectin binding proteins. *Microbiology (Reading, England)* 2012; 158(Pt. 3):781-790. (*)
96. Maddocks SE, Jenkins RE. Honey: A sweet solution to the growing problem of antimicrobial resistance. *Future Microbiol.* 2013; 8(11): 1419-29. (*, **)

97. Merckoll P, Jonassen TO, Vad ME, et al. Bacteria, biofilm and honey: A study of the effects of honey on 'planktonic' and biofilm-embedded chronic wound bacteria; *Scand J Infect Dis* 2009; 41(5):341-347. (*)
98. Müller P, Alber DG, Turnbull L, et al. Synergism between Medihoney and rifampicin against methicillin-resistant *Staphylococcus aureus* (MRSA). *PLoS ONE* 2013; 8(2):e57679.doi:10.1371/journal.pone.0057679*
99. Okhiria OA, Henriques AFM, Burton NF, Cooper RA. Honey modulates biofilms of *Pseudomonas aeruginosa* in a time and dose dependent manner. *J ApiProd and ApiMed Sci.* 2009. 1(1): 6-10. (*)
100. Packer JM, Irish J, Herbert BR, et al. Specific non-peroxide antibacterial effect of manuka honey on the *Staphylococcus aureus* proteome. *Int J Antimicrob Agents* 2012; 40(1): 43-50. (^)
101. Schmidlin P, English H, Duncan W, et al. Antibacterial potential of manuka honey against three oral bacteria in vitro. *Swiss Dental Journal* 2014; 124: 922-7. (*)
102. Sell SA, Wolfe PS, Spence AJ, et al. A preliminary study on the potential of manuka honey and platelet-rich plasma in wound healing. *Int J Biomaterials* 2012;;1-14 (*)
103. Tirado D, Hudson N, Maldonado C. Efficacy of medical grade honey against multidrug-resistant organisms of operational significance: Part 1. *J Trauma Acute Care Surg.* 2014;77(3 Suppl 2):S204-7. (*)
104. Tonks AJ, Dudley E, Porter N, Parton J, Brazier J, Smith E, Tonks A. A 5.8kDa component of Manuka honey stimulates immune cells via TLR4. *J Leukoc Biol* 2007; 82:1147-55. (*)
105. White R. Manuka honey in wound management: greater than the sum of its parts? *J Wound Care.* 2016 Sep;25(9):539-43. doi: 10.12968/jowc.2016.25.9.539.
106. Wilkinson JM, Cavanagh, MA. Antibacterial activity of 13 Honeys against *Escherichia coli* and *Pseudomonas aeruginosa*. *J Med Food* 2005; 8(1):100-3. (*)

Integra Lifesciences Italy S.p.A.
Centro Direzionale Milano Fiori
Strada 6, Palazzo N3
20089 Rozzano (MI) - Italy
P.Iva e Cod.Fisc. 0928446096
ROSA ANNA MARIA BARCHI
Procuratore

Rosa Anna Maria Barchi